EP3723761A2 - A solid oral dosage form comprising linagliptin - Google Patents

A solid oral dosage form comprising linagliptin

Info

Publication number
EP3723761A2
EP3723761A2 EP18914956.0A EP18914956A EP3723761A2 EP 3723761 A2 EP3723761 A2 EP 3723761A2 EP 18914956 A EP18914956 A EP 18914956A EP 3723761 A2 EP3723761 A2 EP 3723761A2
Authority
EP
European Patent Office
Prior art keywords
dosage form
oral dosage
solid oral
weight
form according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18914956.0A
Other languages
German (de)
French (fr)
Other versions
EP3723761A4 (en
Inventor
Ali TÜRKYILMAZ
Nur PEHLIVAN AKALIN
Merve ERGUN DONMEZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanovel Ilac Sanayi ve Ticaret AS
Original Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi ve Ticaret AS filed Critical Sanovel Ilac Sanayi ve Ticaret AS
Publication of EP3723761A2 publication Critical patent/EP3723761A2/en
Publication of EP3723761A4 publication Critical patent/EP3723761A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • the present invention relates to a solid oral dosage form comprising linagliptin and at least one binder.
  • Linagliptin is used for type 2 or non-insulin dependent diabetes. It is a selective, orally administered, xanthine based dipeptidyl peptidase-4 (DPP-4) inhibitor used as an adjunct to diet and exercise to improve glycemic control. DPP-4 inhibitors work by blocking the action of DPP-4, an enzyme which destroys the hormone incretin.
  • DPP-4 inhibitors work by blocking the action of DPP-4, an enzyme which destroys the hormone incretin.
  • DPP-4 inhibitors work by blocking the action of DPP-4, an enzyme which destroys the hormone incretin.
  • GLP-1 glucagon-like peptide-1
  • GIP glucose-dependent insulinotropic peptide
  • Linagliptin works by binding to DPP-4 and preventing it from breaking down the GLP-1 and GIP. This increases the levels of these hormones in the body and so increases their effect on controlling blood sugar.
  • linagliptin 8-[(3R)-3-aminopiperidin-1 -yl]-7-but-2-yn-1 -yl)-3-methyl-1 - [(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1 H-purine-2,6-dione and its chemical structure is shown in the Formula I.
  • WO2014/026939 patent application discloses a pharmaceutical composition comprising linagliptin or salts thereof with mannitol, copovidone, and magnesium stearate, a process for the preparation of the pharmaceutical composition.
  • a pharmaceutical composition comprising linagliptin or salts thereof with mannitol, copovidone, and magnesium stearate, a process for the preparation of the pharmaceutical composition.
  • mannitol, copovidone, and magnesium stearate a process for the preparation of the pharmaceutical composition.
  • the main object of the present invention is to provide high stability of linagliptin and a long shelf life by the help of selection of excipients in a certain ratio.
  • Another aim of the present invention is to provide a pharmaceutical dosage form comprising linagliptin which has a long shelf life, a short disintegration time, desired dissolution properties and enables a high bioavailability of linaglitpin in a patient.
  • linagliptin refers to not only linagliptin, but also its other pharmaceutically acceptable salt, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs and pharmaceutically acceptable prodrugs thereof.
  • the linagliptin is present as amorphous linagliptin, crystalline linagliptin having polymorphic form A, crystalline linagliptin having polymorphic form B and/or crystalline linagliptin having polymorphic form C or mixtures thereof.
  • the linagliptin is present as a mixture of crystalline linagliptin having polymorphic form A and crystalline linagliptin having polymorphic form B.
  • the pharmaceutical solid oral dosage form comprises linagliptin as an active agent and at least one binder in which the weight ratio of linagliptin to binder is between 0.1 and 6.0. This ratio is important in order to providing high stability of linagliptin and improved flow properties.
  • the weight ratio of linagliptin to binder is between 0.3 and 3.0 or between 0.5 and 2.0.
  • the amount of linagliptin in the composition is between 1 .0% and 10.0% by weight, preferably it is between 2.0% and 7.0%, more preferably it is between 2.5% and 6.0%.
  • particle size means the cumulative volume size distrubition as tested by any conventionally accepted method such as the laser diffraction method (i.e. Malvern Mastersizer 2000 analysis).
  • d (0.9) means the size at which %90 by volume of the particles are finer.
  • linagliptin has a d (0.9) particle size less than 100 pm, preferably linagliptin has a d (0.9) particle size less than 50 pm. This property provides improved flow properties.
  • Suitable binders are selected from the group comprising povidone, copovidone, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, mannitol, gelatin, pullulan, sodium alginate or mixtures thereof.
  • the present invention comprises one or more binders in an amount of from about 1% to about 20% by weight of the composition.
  • DPP-4 inhibitors are not very stable compounds.
  • amine group containing DPP-4 inhibitors like linagliptin may react with many excipients or impurities of excipients.
  • binder ensures high stability of linagliptin in a solid oral dosage composition.
  • povidone is used as binder in the present invention. Povidone has also disintegration property and it is used to enhance dissolution of poorly soluble drugs from solid-dosage forms.
  • binder is povidone and the amount of povidone in the composition is 1.0% and 5.0% by weight.
  • the pharmaceutical acceptable excipients used in the present invention are selected from the group consisting of fillers, disintegrants, lubricants, and film coating agents.
  • Suitable fillers are selected from the group comprising microcrystalline cellulose, mannitol, spray-dried mannitol, lactose, lactose monohydrate, starch, dextrose, sucrose, fructose, maltose, sorbitol, xylitol, inositol, kaolin, inorganic salts, calcium salts, polysaccharides, dicalcium phosphate, sodium chloride, dextrates, lactitol, maltodextrin, sucrose-maltodextrin mixture, trehalose, sodium carbonate, sodium bicarbonate, calcium carbonate or mixtures thereof.
  • microcrystalline cellulose is a filler which has the best flowability properties among the other fillers. In this invention, it further improves the disintegration of compositon as well as being a filler. In addition, it further enhances the compressibility by increasing the hardness of the tablet.
  • the amount of microcrystalline cellulose is in the range of 70.0 to 90 %, preferably 76.0 to 88.0 %, more preferably it is 80.0 to 85.0 % by weight of total composition.
  • Suitable disintegrants are selected from the group comprising sodium starch glycolate, cross- linked polyvinil pyrrolidone (crospovidone), povidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose, pregelatinized starch, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, carboxymethyl cellulose, docusate sodium, guar gum, low substituted hydroxypropyl cellulose, polyacryline potassium, sodium alginate, corn starch, alginic acid, alginates, sodium dodecyl sulphate, sodium glycine carbonate, sodium lauryl sulphate or mixtures thereof.
  • crospovidone cross- linked polyvinil pyrrolidone
  • povidone povidone
  • croscarmellose sodium low-substituted hydroxypropyl cellulose
  • pregelatinized starch sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, carboxymethyl cellulose, docusate sodium, gu
  • disintegrant that is neither too much nor too little to detrimentally alter the release of the active ingredient should be used to form solid oral dosage forms provided herein.
  • disintegrants can be mixed with other excipient to increase effective disintegration of the tablet into smaller fragments.
  • disintegrant is sodium starch glycolate, is also known as superdisintegrant, and the amount of sodium starch glycolate is in the range of 3.0% to 8.0% and thus desired level of dissolution rate is provided.
  • povidone and sodium starch glycolate provides desired short disintegration time and desired dissolution properties in composition.
  • the weight ratio of sodium starch glycolate to povidone is between 0.2 and 10.0 or 0.6 and 8.0.
  • the lubricant is selected from the group comprising sodium stearyl fumarate, magnesium stearate, polyethylene glycol (PEG), sodium lauryl sulphate, magnesium lauryl sulphate, fumaric acid, glyceryl palmitostearate, hydrogenated natural oils, zinc stearate, calcium stearate, silica, talc, stearic acid, paraffin or mixtures thereof, preferably sodium stearyl fumarate. Coating may also preferably be used for moisture protection.
  • Suitable coating agents are selected from the group comprising polymethacrylates, hydroxypropyl methylcellulose, lactose monohydrate, hydroxypropyl cellulose, polyvinyl alcohol (PVA), polyethylene glycol (PEG), talc, glycerine, polyvinyl alcohol-polyethylene glycol copolymers (Kollicoat® IR), ethylcellulose dispersions (Surelease®), polyvinylprolidone, polyvinylprolidone-vinyl acetate copolymer (PVP-VA), all kinds of Opadry®, pigments, dyes, titanium dioxide, macrogol, coloring agent or mixtures thereof.
  • Suitable coloring agents are selected from the group comprising ferric oxide, titanium dioxide, Food, Drug & Cosmetic (FD&C) dyes (such as; FD&C blue, FD&C green, FD&C red, FD&C yellow, FD&C lakes), ponceau, indigo Drug & Cosmetic (D&C) blue, indigotine FD&C blue, carmoisine indigotine (indigo Carmine); iron oxides (such as; iron oxide red, yellow, black), quinoline yellow, flaming red, carmine, carmoisine, sunset yellow or mixtures thereof.
  • FD&C Food, Drug & Cosmetic
  • the pharmaceutical composition of the present invention comprises linagliptin or a pharmaceutically acceptable salt thereof, povidone, sodium stearyl fumarate, sodium starch glycolate, microcrystalline cellulose.
  • Solid oral dosage is used for having effective stability and bioavailability.
  • Another embodiment of the present invention is a pharmaceutical composition in the form of a solid oral dosage form.
  • the solid oral dosage form is tablet or capsule or pastilles or strip.
  • the solid oral dosage form is tablet. Tablet may be consisted of separated compartments or layer.
  • the pharmaceutical combination is formulated as tablets comprising film-coated tablets, compressed tablets, coated or uncoated tablets, multilayer tablets, mini tablets, bilayer tablet, pellet in tablet, buccal tablets, sublingual tablets, effervescent tablets, immediate release tablets, core-in-tablet, modified release tablets, tablet-in-tablet, orally disintegrating tablets, gastric disintegrating tablets, chewable tablet, dispersing tablet, lozenges.
  • the pharmaceutical combination is formulated as film coated tablet.
  • the pharmaceutical combination can be prepared in tablet form. Tablet comprises at least one type of particle, for example; mini-tablets, pellets, agglomerates, granules, powders, liposomes, sphericles or mixtures thereof.
  • each type of particle comprises at least one active agent.
  • pharmaceutical combination may comprise a film coating if necessary.
  • Capsule comprises of at least one type of particle, for example; mini-capsules, mini-tablets, pellets, agglomerates, granules, powders, liposomes, sphericles or mixtures thereof.
  • the dosage unit form of composition is mini capsules in capsule wherein the mini-capsules comprise at least one active agent.
  • the dosage unit form of composition is mini-tablets in capsule wherein a mini-tablets comprise at least one active agent.
  • the dosage unit form of composition is pellets in capsule wherein pellets comprise at least one active agent.
  • the composition comprises;
  • the composition comprises;
  • the pharmaceutical composition of the present invention can be prepared, using standard techniques and manufacturing processes well known in the art, such as direct compression, wet and dry granulation.
  • the formulation when the formulation is prepared with wet granulation, the formulation has desired stability and desired dissolution rate.
  • Suitable granulation solutions are selected from a group comprising pure water, ethyl alcohol, glycerin, sorbitol, polyethylene glycol, propylene glycol, isopropyl alcohol or mixtures thereof, preferably the granulation solution is pure water.
  • the process for preparation of the pharmaceutical composition comprises the following steps:
  • Example 1 Film coated tablet comprising linagliptin
  • Example 2 Solid oral dosage form comprising linagliptin
  • the process for preparation of the pharmaceutical composition comprises the following steps:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a solid oral dosage form comprising linagliptin and at least one binder.

Description

A SOLID ORAL DOSAGE FORM COMPRISING LINAGLIPTIN
Field of the Invention
The present invention relates to a solid oral dosage form comprising linagliptin and at least one binder.
Background of the Invention
Linagliptin is used for type 2 or non-insulin dependent diabetes. It is a selective, orally administered, xanthine based dipeptidyl peptidase-4 (DPP-4) inhibitor used as an adjunct to diet and exercise to improve glycemic control. DPP-4 inhibitors work by blocking the action of DPP-4, an enzyme which destroys the hormone incretin. There are two types of incretin hormones found in the body, called glucagon-like peptide-1 (GLP-1 ) and glucose-dependent insulinotropic peptide (GIP). These hormones are naturally produced by the body in response to food intake. Their function is to help the body produce more insulin only when it is needed and reduce the amount of glucose being produced by the liver when it is not needed. Linagliptin works by binding to DPP-4 and preventing it from breaking down the GLP-1 and GIP. This increases the levels of these hormones in the body and so increases their effect on controlling blood sugar.
The chemical name of linagliptin is 8-[(3R)-3-aminopiperidin-1 -yl]-7-but-2-yn-1 -yl)-3-methyl-1 - [(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1 H-purine-2,6-dione and its chemical structure is shown in the Formula I.
Formula I
WO2014/026939 patent application discloses a pharmaceutical composition comprising linagliptin or salts thereof with mannitol, copovidone, and magnesium stearate, a process for the preparation of the pharmaceutical composition. There still remains a need in the art to provide an improved pharmaceutical composition of linagliptin. At this invention provides having high stability of linagliptin, dissolution rate, and therefore a high bioavailability and a long-term stability.
Detailed Description of the Invention
The main object of the present invention is to provide high stability of linagliptin and a long shelf life by the help of selection of excipients in a certain ratio.
Another aim of the present invention is to provide a pharmaceutical dosage form comprising linagliptin which has a long shelf life, a short disintegration time, desired dissolution properties and enables a high bioavailability of linaglitpin in a patient.
The term "linagliptin" as used throughout the specification refers to not only linagliptin, but also its other pharmaceutically acceptable salt, pharmaceutically acceptable solvates, pharmaceutically acceptable hydrates, pharmaceutically acceptable enantiomers, pharmaceutically acceptable derivatives, pharmaceutically acceptable polymorphs and pharmaceutically acceptable prodrugs thereof.
The linagliptin is present as amorphous linagliptin, crystalline linagliptin having polymorphic form A, crystalline linagliptin having polymorphic form B and/or crystalline linagliptin having polymorphic form C or mixtures thereof.
In one embodiment of the invention, the linagliptin is present as a mixture of crystalline linagliptin having polymorphic form A and crystalline linagliptin having polymorphic form B.
In one embodiment of the invention, the pharmaceutical solid oral dosage form comprises linagliptin as an active agent and at least one binder in which the weight ratio of linagliptin to binder is between 0.1 and 6.0. This ratio is important in order to providing high stability of linagliptin and improved flow properties.
In one embodiment of the invention, the weight ratio of linagliptin to binder is between 0.3 and 3.0 or between 0.5 and 2.0.
In one embodiment of the invention, the amount of linagliptin in the composition is between 1 .0% and 10.0% by weight, preferably it is between 2.0% and 7.0%, more preferably it is between 2.5% and 6.0%. As used here in,‘particle size’ means the cumulative volume size distrubition as tested by any conventionally accepted method such as the laser diffraction method (i.e. Malvern Mastersizer 2000 analysis). The term d (0.9) means the size at which %90 by volume of the particles are finer.
In one embodiment of the invention, linagliptin has a d (0.9) particle size less than 100 pm, preferably linagliptin has a d (0.9) particle size less than 50 pm. This property provides improved flow properties.
Suitable binders are selected from the group comprising povidone, copovidone, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, mannitol, gelatin, pullulan, sodium alginate or mixtures thereof.
The present invention comprises one or more binders in an amount of from about 1% to about 20% by weight of the composition.
In general, DPP-4 inhibitors are not very stable compounds. Especially, in solid dosage forms, amine group containing DPP-4 inhibitors like linagliptin may react with many excipients or impurities of excipients. In this invention, it has been surprisingly found that using binder ensures high stability of linagliptin in a solid oral dosage composition. Especially povidone is used as binder in the present invention. Povidone has also disintegration property and it is used to enhance dissolution of poorly soluble drugs from solid-dosage forms.
In one embodiment of the invention, binder is povidone and the amount of povidone in the composition is 1.0% and 5.0% by weight.
In another embodiment, the pharmaceutical acceptable excipients used in the present invention are selected from the group consisting of fillers, disintegrants, lubricants, and film coating agents.
Suitable fillers are selected from the group comprising microcrystalline cellulose, mannitol, spray-dried mannitol, lactose, lactose monohydrate, starch, dextrose, sucrose, fructose, maltose, sorbitol, xylitol, inositol, kaolin, inorganic salts, calcium salts, polysaccharides, dicalcium phosphate, sodium chloride, dextrates, lactitol, maltodextrin, sucrose-maltodextrin mixture, trehalose, sodium carbonate, sodium bicarbonate, calcium carbonate or mixtures thereof. According to one embodiment, microcrystalline cellulose is a filler which has the best flowability properties among the other fillers. In this invention, it further improves the disintegration of compositon as well as being a filler. In addition, it further enhances the compressibility by increasing the hardness of the tablet.
In this embodiment, the amount of microcrystalline cellulose is in the range of 70.0 to 90 %, preferably 76.0 to 88.0 %, more preferably it is 80.0 to 85.0 % by weight of total composition.
Suitable disintegrants are selected from the group comprising sodium starch glycolate, cross- linked polyvinil pyrrolidone (crospovidone), povidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose, pregelatinized starch, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, carboxymethyl cellulose, docusate sodium, guar gum, low substituted hydroxypropyl cellulose, polyacryline potassium, sodium alginate, corn starch, alginic acid, alginates, sodium dodecyl sulphate, sodium glycine carbonate, sodium lauryl sulphate or mixtures thereof.
A sufficient amount of disintegrant that is neither too much nor too little to detrimentally alter the release of the active ingredient should be used to form solid oral dosage forms provided herein. However, disintegrants can be mixed with other excipient to increase effective disintegration of the tablet into smaller fragments.
In one embodiment of the invention, disintegrant is sodium starch glycolate, is also known as superdisintegrant, and the amount of sodium starch glycolate is in the range of 3.0% to 8.0% and thus desired level of dissolution rate is provided.
Furthermore, the combination of povidone and sodium starch glycolate provides desired short disintegration time and desired dissolution properties in composition.
According to an embodiment of the present invention, the weight ratio of sodium starch glycolate to povidone is between 0.2 and 10.0 or 0.6 and 8.0.
According to another embodiment, the lubricant is selected from the group comprising sodium stearyl fumarate, magnesium stearate, polyethylene glycol (PEG), sodium lauryl sulphate, magnesium lauryl sulphate, fumaric acid, glyceryl palmitostearate, hydrogenated natural oils, zinc stearate, calcium stearate, silica, talc, stearic acid, paraffin or mixtures thereof, preferably sodium stearyl fumarate. Coating may also preferably be used for moisture protection. Suitable coating agents are selected from the group comprising polymethacrylates, hydroxypropyl methylcellulose, lactose monohydrate, hydroxypropyl cellulose, polyvinyl alcohol (PVA), polyethylene glycol (PEG), talc, glycerine, polyvinyl alcohol-polyethylene glycol copolymers (Kollicoat® IR), ethylcellulose dispersions (Surelease®), polyvinylprolidone, polyvinylprolidone-vinyl acetate copolymer (PVP-VA), all kinds of Opadry®, pigments, dyes, titanium dioxide, macrogol, coloring agent or mixtures thereof.
Suitable coloring agents are selected from the group comprising ferric oxide, titanium dioxide, Food, Drug & Cosmetic (FD&C) dyes (such as; FD&C blue, FD&C green, FD&C red, FD&C yellow, FD&C lakes), ponceau, indigo Drug & Cosmetic (D&C) blue, indigotine FD&C blue, carmoisine indigotine (indigo Carmine); iron oxides (such as; iron oxide red, yellow, black), quinoline yellow, flaming red, carmine, carmoisine, sunset yellow or mixtures thereof.
Preferably, the pharmaceutical composition of the present invention comprises linagliptin or a pharmaceutically acceptable salt thereof, povidone, sodium stearyl fumarate, sodium starch glycolate, microcrystalline cellulose.
Solid oral dosage is used for having effective stability and bioavailability. Another embodiment of the present invention is a pharmaceutical composition in the form of a solid oral dosage form.
In this present invention, the solid oral dosage form is tablet or capsule or pastilles or strip.
In this present invention, the solid oral dosage form is tablet. Tablet may be consisted of separated compartments or layer.
An embodiment of this present invention, the pharmaceutical combination is formulated as tablets comprising film-coated tablets, compressed tablets, coated or uncoated tablets, multilayer tablets, mini tablets, bilayer tablet, pellet in tablet, buccal tablets, sublingual tablets, effervescent tablets, immediate release tablets, core-in-tablet, modified release tablets, tablet-in-tablet, orally disintegrating tablets, gastric disintegrating tablets, chewable tablet, dispersing tablet, lozenges.
Preferably, the pharmaceutical combination is formulated as film coated tablet. In this present invention, the pharmaceutical combination can be prepared in tablet form. Tablet comprises at least one type of particle, for example; mini-tablets, pellets, agglomerates, granules, powders, liposomes, sphericles or mixtures thereof.
An embodiment of this present invention, each type of particle comprises at least one active agent.
In this present invention, pharmaceutical combination may comprise a film coating if necessary.
In this present invention, pharmaceutical combination can be prepared in capsule form. Capsule comprises of at least one type of particle, for example; mini-capsules, mini-tablets, pellets, agglomerates, granules, powders, liposomes, sphericles or mixtures thereof.
An embodiment of this present invention, the dosage unit form of composition is mini capsules in capsule wherein the mini-capsules comprise at least one active agent.
An embodiment of this present invention, the dosage unit form of composition is mini-tablets in capsule wherein a mini-tablets comprise at least one active agent.
An embodiment of this present invention, the dosage unit form of composition is pellets in capsule wherein pellets comprise at least one active agent.
In one embodiment of the present invention, the composition comprises;
a) 2.0 - 10.0% by weight of linagliptin
b) 80.0 - 85.0% by weight of filler
c) 1 .5 - 4.0% by weight of binder
d) 3.5 - 6.0% by weight of disintegrant
e) 0.1 - 3.0% by weight of lubricant
f) 1 .0 - 5.0% by weight of coating agents In one embodiment of the present invention, the composition comprises;
a) 1 .0 - 10.0% by weight of linagliptin
b) 70.0 - 90.0% by weight of microcrystalline cellulose
c) 1 .0 - 5.0% by weight of povidone
d) 3.0 - 8.0% by weight of sodium starch glycolate
e) 0.1 - 5.0% by weight of sodium stearyl fumarate
f) 0.5 - 8.0% by weight of coating agents
The pharmaceutical composition of the present invention can be prepared, using standard techniques and manufacturing processes well known in the art, such as direct compression, wet and dry granulation.
According to one embodiment of the present invention, it has been found that when the formulation is prepared with wet granulation, the formulation has desired stability and desired dissolution rate.
Suitable granulation solutions are selected from a group comprising pure water, ethyl alcohol, glycerin, sorbitol, polyethylene glycol, propylene glycol, isopropyl alcohol or mixtures thereof, preferably the granulation solution is pure water.
An embodiment of the present invention, the process for preparation of the pharmaceutical composition comprises the following steps:
a) Mixing linagliptin, microcrystalline cellulose and sodium starch glycolate
b) Granulating povidone with pure water on a separate tank
c) Mixing step (a) mixture and step (b) mixture
d) Drying the mixture, then sieving the mixture
e) Adding sodium stearyl fumarate and then mixing
f) Then, pressing to form tablet
g) Coating tablets with coating agents. Example 1 : Film coated tablet comprising linagliptin
Example 2: Solid oral dosage form comprising linagliptin
Process for example 1 or 2:
The process for preparation of the pharmaceutical composition comprises the following steps:
a) Mixing linagliptin, microcrystalline cellulose and sodium starch glycolate
b) Granulating povidone with pure water on a separate tank
c) Mixing step (a) mixture and step (b) mixture
d) drying the mixture, then sieving the mixture
e) Adding sodium stearyl fumarate and then mixing
f) Then, pressing to form tablet
g) Coating tablets with coating agents.

Claims

1. A pharmaceutical solid oral dosage form comprising linagliptin as an active agent and at least one binder in which the weight ratio of linagliptin to binder is between 0.1 and 6.0.
2. The pharmaceutical solid oral dosage form according to claim 1 , wherein the weight ratio of linagliptin to binder is between 0.3 and 3.0.
3. The pharmaceutical solid oral dosage form according to claim 2, wherein the weight ratio of linagliptin to binder is between 0.5 and 2.0.
4. The pharmaceutical solid oral dosage form according to claim 3, wherein the amount of linagliptin in the composition is between 1.0% and 10.0% by weight, preferably it is between 2.0% and 7.0%.
5. The pharmaceutical solid oral dosage form according to claim 4, wherein linagliptin has a d (0.9) particle size less than 100 pm.
6. The pharmaceutical solid oral dosage form according to claim 5, wherein linagliptin has a d (0.9) particle size less than 50 pm.
7. The pharmaceutical solid oral dosage form according to claim 1 , wherein at least one binders are selected from the group comprising povidone, copovidone, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, mannitol or mixtures thereof.
8. The pharmaceutical solid oral dosage form according to claim 7, wherein the binder is povidone.
9. The pharmaceutical solid oral dosage form according to claim 8, wherein the amount of povidone in the composition is 1 .0% and 5.0% by weight.
10. The pharmaceutical solid oral dosage form according to any preceding claims, further comprising pharmaceutical acceptable excipients which are selected from the group consisting of fillers, disintegrants, lubricants or film coating agents.
1 1. The pharmaceutical solid oral dosage form according to claim 10, wherein disintegrant is selected from the group comprising sodium starch glycolate, cross- linked polyvinil pyrrolidone (crospovidone), povidone, croscarmellose sodium, low- substituted hydroxypropyl cellulose, pregelatinized starch, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, carboxymethyl cellulose, docusate sodium, guar gum, low substituted hydroxypropyl cellulose, polyacryline potassium, sodium alginate, corn starch, alginic acid, alginates, sodium dodesyl sulphate, sodium glycine carbonate, sodium lauryl sulphate or mixtures thereof.
12. The pharmaceutical solid oral dosage form according to claim 1 1 , wherein disintegrant is sodium starch glycolate.
13. The pharmaceutical solid oral dosage form according to claim 12, wherein the amount of sodium starch glycolate is in the range of 3.0% to 8.0%.
14. The pharmaceutical solid oral dosage form according to claim 9 or 13, wherein the weight ratio of sodium starch glycolate to povidone is between 0.2 and 10.0.
15. The pharmaceutical solid oral dosage form according to any preceding claims, wherein the solid oral dosage form is tablet or capsule or pastilles or strip.
16. The pharmaceutical solid oral dosage form according to claim 15, wherein the solid oral dosage form is tablet.
17. The pharmaceutical solid oral dosage form according to claim 16, the composition comprising;
a) 2.0 - 10.0% by weight of linagliptin
b) 80.0 - 85.0% by weight of filler
c) 1 .5 - 4.0% by weight of binder
d) 3.5 - 6.0% by weight of disintegrant
e) 0.1 - 3.0% by weight of lubricant
f) 1 .0 - 5.0% by weight of coating agents
18. The pharmaceutical solid oral dosage form according to claim 16, the composition comprising;
a) 1 .0 - 10.0% by weight of linagliptin
b) 70.0 - 90.0% by weight of microcrystalline cellulose
c) 1 .0 - 5.0% by weight of povidone
d) 3.0 - 8.0% by weight of sodium starch glycolate
e) 0.1 - 5.0% by weight of sodium stearyl fumarate
f) 0.5 - 8.0% by weight of coating agents
19. Process for preparing the pharmaceutical solid oral dosage form according to claim 18, comprising the following steps;
a) Mixing linagliptin, microcrystalline cellulose and sodium starch glycolate b) Granulating povidone with pure water on a separate tank
c) Mixing step (a) mixture and step (b) mixture
d) Drying the mixture, then sieving the mixture
e) Adding sodium stearyl fumarate and then mixing
f) Then, pressing to form tablet
g) Coating tablets with coating agents
EP18914956.0A 2017-12-15 2018-12-14 A solid oral dosage form comprising linagliptin Pending EP3723761A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2017/20515A TR201720515A2 (en) 2017-12-15 2017-12-15 A SOLID ORAL DOSAGE FORM CONTAINING LINAGLIPTIN
PCT/TR2018/050812 WO2019203755A2 (en) 2017-12-15 2018-12-14 A solid oral dosage form comprising linagliptin

Publications (2)

Publication Number Publication Date
EP3723761A2 true EP3723761A2 (en) 2020-10-21
EP3723761A4 EP3723761A4 (en) 2021-06-30

Family

ID=67900883

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18914956.0A Pending EP3723761A4 (en) 2017-12-15 2018-12-14 A solid oral dosage form comprising linagliptin

Country Status (4)

Country Link
EP (1) EP3723761A4 (en)
CA (1) CA3085455C (en)
TR (1) TR201720515A2 (en)
WO (1) WO2019203755A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022173406A1 (en) * 2021-02-15 2022-08-18 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A process for formulations of linagliptin or a pharmaceutically acceptable salt thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32427A (en) * 2009-02-13 2010-09-30 Boheringer Ingelheim Internat Gmbh PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL FORM, PROCEDURE FOR PREPARATION, METHODS OF TREATMENT AND USES OF THE SAME
WO2013128379A2 (en) 2012-02-27 2013-09-06 Dr. Reddy's Laboratories Limited Crystalline polymorphic forms of linagliptin
US20140100236A1 (en) * 2012-10-09 2014-04-10 Boehringer Ingelheim International Gmbh Use of selectively moisture-adjusted tabletting material in the production of mechanically stable tablets which contain at least one hydrate-forming active substance and/or adjuvant relevant to the mechanical stability of the tablets, particularly arginine-containing tablets
WO2014080383A1 (en) * 2012-11-26 2014-05-30 Ranbaxy Laboratories Limited Pharmaceutical composition of dipeptidyl peptidase-iv (dpp-iv) inhibitors in combination with other antidiabetics
WO2014080384A1 (en) 2012-11-26 2014-05-30 Ranbaxy Laboratories Limited Pharmaceutical composition of linagliptin
CN106138059A (en) 2015-03-27 2016-11-23 天津汉瑞药业有限公司 A kind of stable Li Gelieting pharmaceutical composition
EP3156048A1 (en) 2015-10-13 2017-04-19 Galenicum Health S.L. Stable pharmaceutical composition of linagliptin in the form of immediate release tablets

Also Published As

Publication number Publication date
CA3085455C (en) 2022-08-16
WO2019203755A3 (en) 2020-01-16
TR201720515A2 (en) 2019-07-22
EP3723761A4 (en) 2021-06-30
CA3085455A1 (en) 2019-10-24
WO2019203755A2 (en) 2019-10-24

Similar Documents

Publication Publication Date Title
US11033552B2 (en) DPP IV inhibitor formulations
US11819577B2 (en) Fixed dose pharmaceutical composition of valsartan and sacubitril
EP3731837A2 (en) The combination comprising linagliptin and metformin
WO2014080384A1 (en) Pharmaceutical composition of linagliptin
EP2468268B1 (en) Combination composition of vildagliptin and gliclazide
EP3781135A2 (en) Solid oral pharmaceutical compositions comprising sitagliptin
WO2017208136A1 (en) Pharmaceutical composition of dapagliflozin co-crystal
US20190110994A1 (en) Pharmaceutical composition of dapagliflozin
EP2848242A1 (en) Orally disintegrating formulations of Linagliptin
CA3085455C (en) A solid oral dosage form comprising linagliptin
WO2020009675A2 (en) Solid oral pharmaceutical compositions of linagliptin
EP4019003A1 (en) Pharmaceutical formulations of linagliptin
WO2022153330A1 (en) Pharmaceutical compositions comprising acalabrutinib
WO2019132833A1 (en) The modified release combination comprising linagliptin and metformin
WO2022173406A1 (en) A process for formulations of linagliptin or a pharmaceutically acceptable salt thereof
US20120121722A1 (en) Atazanavir formulations
WO2024084496A1 (en) Pharmaceutical compositions comprising acalabrutinib maleate
US20230310327A1 (en) Pharmaceutical compositions comprising ribociclib
EP4385501A1 (en) A pharmaceutical formulation comprising linagliptin, pioglitazone and a sglt-2 inhibitor
WO2005030219A1 (en) Method of stabilizing diarylvinylene compound
EP3731931A2 (en) Modified release formulations of fesoterodine
CN116490178A (en) Composition of SGLT-2 inhibitor and angiotensin receptor blocker and application
EP3731823A1 (en) A pharmaceutical formulation for oral administration comprising dabigatran etexilate
EP3354262A1 (en) Enteric coated pharmaceutical compositions of dexlansoprazole
EA040745B1 (en) PHARMACEUTICAL COMPOSITION CONTAINING TWO DIFFERENT ACTIVE INGREDIENTS AND METHOD FOR ITS PRODUCTION

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200714

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20210601

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/522 20060101AFI20210526BHEP

Ipc: A61K 47/00 20060101ALI20210526BHEP

Ipc: A61P 3/10 20060101ALI20210526BHEP

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230708

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20231108